Evidence map›Paper›PMID 33554079›Full record

ArticleEClinicalMedicine2021

Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy.

Lu Zhang, Lingeng Wu, Qiuying Chen, Bin Zhang, Jing Liu, Shuyi Liu, Xiaokai Mo, Minmin Li, Zhuozhi Chen, Luyan Chen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lu ZhangDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Lingeng WuDepartment of Interventional Therapy, Cancer Centre, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Qiuying ChenDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Bin ZhangDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Jing LiuDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Shuyi LiuDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Xiaokai MoDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Minmin LiDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Zhuozhi ChenDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Luyan ChenDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Jingjing YouDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Zhe JinDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Xudong ChenMinimally Invasive Interventional Treatment Centre, Shenzhen People's Hospital (The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical Medical College of Jinan University), Shenzhen, Guangdong, China.
Zejian ZhouDepartment of Interventional Therapy, Cancer Centre, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Shuixing ZhangDepartment of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperprogressive disease (HPD) is a new progressive pattern in patients with advanced hepatocellular carcinoma (HCC) treated with programmed cell death 1 (PD-1) inhibitors. We aimed to investigate risk factors associated with HPD in advanced HCC patients undergoing anti-PD-1 therapy.

methodsA total of 69 patients treated with anti-PD-1 therapy between March 2017 and January 2020 were included. HPD was determined according to the time to treatment failure, tumour growth rate, and tumour growth rate ratio. Univariate and multivariate analyses were performed to identify clinical variables significantly associated with HPD. A risk model was constructed based on clinical variables with prognostic significance for HPD.

findingsOverall, 10 (14·49%) had HPD. Haemoglobin level, portal vein tumour thrombus, and Child-Pugh score were significantly associated with HPD. The risk model had an area under the curve of 0·931 (95% confidence interval, 0·844-1·000). Patients with HPD had a significantly shorter overall survival (OS) than that of the patients with non-HPD (

interpretationWe identified three clinical variables as risk factors for HPD, providing an opportunity to aid the pre-treatment evaluation of the risk of HPD in patients treated with immunotherapy.

fundingThis study was funded by the National Natural Science Foundation of China (81571664, 81871323, and 81801665); National Natural Science Foundation of Guangdong Province (2018B030311024); Scientific Research General Project of Guangzhou Science Technology and Innovation Commission (201707010,328); and China Postdoctoral Science Foundation (2016M600145).

Indexed as

Hepatocellular carcinomaHyperprogressive diseaseImmune checkpoint inhibitorsProgrammed cell death 1

Identifiers

PMID33554079
PMCPMC7846667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.